Narrow Your Results

This retrospective case series evaluated 24-month outcomes in patients who received a trabecular microbypass stent (iStent, Glaukos Corp.) for mild to severe pseudoexfoliation glaucoma.

Investigators assessed 1-year safety and efficacy outcomes of voretigene neparvovec (AAV2-hRPE65v2), a gene replacement therapy for RPE65-mediated retinal dystrophies.

Investigators of this retrospective study assessed the rates of vision loss and ocular complications in patients with retinal vasculitis (RV).

Investigators report the safety and efficacy of descemetorhexis without donor tissue as a primary treatment for Fuchs endothelial dystrophy.

In this randomized, multicenter phase 3b trial, investigators analyzed the efficacy of treat-and-extend (TREX) ranibizumab for neovascular AMD.

This small prospective study evaluated the diagnostic value of MRI of the optic nerve head for identifying nonarteritic vs. arteritic anterior ischemic optic neuropathy.

An RNA-based gene therapy made by Dutch biotech company ProQR Therapeutics has received Orphan Drug Designation from the FDA and European Medicines Agency for treatment of Usher syndrome type II, a form of retinitis pigmentosa.

According to the National Eye Institute (NEI), recent developments in dry eye disease research are leading to potential therapies designed to address the underlying causes of disease rather than simply providing symptomatic relief.

This secondary analysis of the Mycotic Ulcer Treatment Trial (MUTT) II clinical trial explores the role of adjuvant oral voriconazole on clinical outcomes in Fusarium keratitis.

Novartis’ proprietary anti-VEGF agent RTH258 (brolucizumab) appears to be noninferior to aflibercept for treatment of neovascular age-related macular degeneration (AMD), according to results from 2 ongoing phase 3 studies.

Investigators assessed the time required to detect statistically significant visual field (VF) progression on standard automated perimetry (SAP) after comparing various frequencies of testing.

Immunomodulatory therapy can be an effective steroid-sparing alternative for treating pediatric intermediate uveitis, according to this retrospective study.

This retrospective, longitudinal study assessed the rate of ophthalmic examinations among youths with diabetes, specifically to monitor screening for diabetic retinopathy (DR).

Investigators compared features and outcomes of open-globe repair based on the choice of anesthesia: regional block with monitored anesthesia care or general anesthesia.

Investigators from a single tertiary eye center found that adding dexamethasone to initial antibiotic therapy may reduce hospital stay duration without inducing serious complications.

A novel, disposable contact lens may effectively slow the progression of myopia in children, according to strong results from a 3-year trial.

This prospective, comparative study looked at visual, refractive, aberrometric and contrast sensitivity outcomes after small incision lenticule extraction (SMILE) and wavefront-guided LASIK.

Preliminary results from an extension study of the phase 2 TANZANITE trial show continued benefits of a proprietary triamcinolone acetonide formulation when used as an adjunct to aflibercept for treatment of macular edema associated with retinal vein occlusion.

Six patients have successfully undergone an experimental vitreoretinal surgery with the assistance of a robot, marking the first use of this procedure inside a living human eye.

Whether you plan to take the Demonstration of Ophthalmic Cognitive Knowledge (DOCK) exam or participate in the new ABO Quarterly Questions pilot program, the Academy has the tools you'll need to ensure success.

German medical device company Implandata has received CE Marking for EyeMate, the first approved IOP-monitoring system to offer 24-hour pressure measurements in patients with primary open-angle glaucoma (POAG).

This retrospective study compared outcomes of conventional strabismus surgery with botulinum toxin injections for treatment of acute-onset comitant esotropia in children aged 2 to 10 years.

A small study published in Nature Methods has found that the CRISPR-Cas9 gene editing technique may insert hundreds of unexpected mutations into the genome.

Nicox, the French-based drugmaker, has announced FDA approval for its new topical ocular formulation of cetirizine (Zerviate) to treat ocular itching associated with allergic conjunctivitis.

Biotech startup TearClear has raised $4.5 million to develop their filter technology, which is designed to provide preservative-free delivery of topical medications.